Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts. The plan was later approved as Chapter 11 liquidation on May 11, 2023.
| Business Activity | PASS |
| Debt Ratio (26,379.90%) | FAIL |
| Cash Ratio (34,304.94%) | FAIL |
| Receivables Ratio (0.00%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | FAIL |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2022-05-05 | -0.18 | -0.22 | -24.5% |
| 2022-03-10 | -0.18 | -0.19 | -7.5% |
| 2021-10-28 | -0.24 | -0.05 | +79.2% |
| 2021-07-29 | -0.18 | -0.06 | +67.3% |
| 2021-04-29 | -0.19 | -0.17 | +8.9% |
| 2021-02-11 | -0.21 | -0.23 | -9.5% |
| 2020-10-29 | -0.30 | -0.08 | +73.3% |
| 2020-07-23 | -0.43 | -0.39 | +9.3% |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Ascentis Independent Advisors | 3.0K | — | 0.0% |
| Motiv8 Investments LLC | 300.0 | — | — |
-$4.6M
0.00
38.321
$1.9M
$15.5M
0.74
0.0%
74
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| QTEX | 0.262 |
| BOY.L | 0.256 |
| KMEFIC.KW | 0.230 |
| FLO | 0.224 |
| HYLN | 0.217 |
| Ticker | Correlation |
|---|---|
| MBAI | -0.412 |
| SLGL | -0.395 |
| ENGRO.KA | -0.359 |
| RUM | -0.339 |
| NGEN | -0.296 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.